BioXcel Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

BioXcel Therapeutics

08/11/2024 16:05

* BioXcel Therapeutics Inc  BTAI.OQ   BTAI.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
14 for the period ending September 30 2024
    * The New Haven Connecticut-based  company is expected to
report a
282.9% increase in revenue to $1.306 million from $341 thousand
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for BioXcel Therapeutics Inc
is
for a loss of 54 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $6.00​, above​ its last closing price
of $0.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.70       -0.71      -0.21     Beat    70.4
 Mar. 31 2024  -0.64       -0.70      -0.87     Missed  -24.6
 Dec. 31 2023  -0.94       -0.91      -0.76     Beat    16.5​
 Sep. 30 2023  -1.34       -1.30      -1.72     Missed  -31.9
 ​​Jun.        -1.80       -1.75      -1.83     Missed  -4.5
 30 2023                                                
 Mar. 31 2023  -1.81       -1.62      -1.84     Missed  -13.7​
 Dec. 31 2022  -1.49       -1.45      -1.95     Missed  -34.8
 Sep. 30 2022  -1.33       -1.35      -1.49     Missed  -10.5
 This summary was machine generated November 8 at 16:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)